Spots Global Cancer Trial Database for Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

Official Title: A Prospective Multicenter Study of Longitudinal Monitoring in Treated Stage III-IV Lung Cancer Patients by Circulating Tumor DNA

Study ID: NCT03664843

Conditions

Carcinoma

Non-small Cell Lung Cancer

Lung Neoplasm

Interventions

Study Description

Brief Summary: Conduct a prospective study in multicenter to confirm the value of circulating tumor DNA in longitudinal monitoring of stage III-IV lung cancer patients.

Detailed Description: The study consists of two phases, the first stage is the exploratory stage of blood collection point which is the appropriate effective time after chemotherapy, radiotherapy, targeted therapy. The second phase, which is the expansion of the first phase, is to determine the precise leading time of ctDNA relative to tumor biomarkers or image evaluation in determining the efficacy of advanced NSCLC cancer therapy. Both stages were divided into three subgroups: the chemotherapy group, the radiotherapy group, and the targeted therapy group.